Aethlon Medical (NASDAQ:AEMD) Rating Increased to Sell at StockNews.com

StockNews.com upgraded shares of Aethlon Medical (NASDAQ:AEMD) to a sell rating in a report published on Wednesday morning.

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Aethlon Medical in a report on Thursday, January 30th.

Aethlon Medical Price Performance

Shares of Aethlon Medical stock opened at $0.58 on Wednesday. The business has a 50-day simple moving average of $0.65 and a 200 day simple moving average of $0.49. Aethlon Medical has a one year low of $0.24 and a one year high of $1.85. The firm has a market capitalization of $8.44 million, a price-to-earnings ratio of -0.37 and a beta of 1.88.

Aethlon Medical (NASDAQ:AEMD) last issued its earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.09. On average, sell-side analysts expect that Aethlon Medical will post -0.82 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of AEMD. Renaissance Technologies LLC bought a new position in Aethlon Medical during the 4th quarter valued at $25,000. Allegiance Financial Group Advisory Services LLC purchased a new stake in Aethlon Medical in the 4th quarter valued at about $26,000. Sassicaia Capital Advisers LLC bought a new position in shares of Aethlon Medical during the 4th quarter worth approximately $31,000. Virtu Financial LLC bought a new position in shares of Aethlon Medical in the fourth quarter valued at approximately $81,000. Finally, Boothbay Fund Management LLC bought a new stake in Aethlon Medical during the fourth quarter worth $186,000. Hedge funds and other institutional investors own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.